Efficacy Study of Folic Acid Supplementation in Adolescent Epileptics
Primary Purpose
Epilepsy
Status
Unknown status
Phase
Phase 3
Locations
India
Study Type
Interventional
Intervention
Folic Acid
Saccharine
Sponsored by
About this trial
This is an interventional prevention trial for Epilepsy focused on measuring Anti-epileptic drugs, Folic acid, Homocysteine
Eligibility Criteria
Inclusion Criteria:
- Diagnosed epileptic patients of either sex with age between 10-19 yrs (<19yrs), coming to the medicine Out Patient /In Patient Departments and undergoing AED therapy for more than 6 months.
- Epileptics with high homocysteine levels i.e. > 10.9 µmol/L (Normal homocysteine levels are 4.3-9.9 µmol/L for male and 3.3-7.2 µmol/L for female adolescent and a high homocysteine concentration is deaned as at least 11.4 µmol/L for male and at least 10.4 µmol/L for female. Gender mean of high homocysteine concentration is 10.9 µmol/L) [5]
Exclusion Criteria:
- Pregnancy and lactation
- Patients with diabetes, Ischemic heart disease (IHD), stroke, malignancy and psychiatric diseases are excluded from study.
- The patients receiving vitamin supplements or who had clinical evidence for an acute illness, renal dysfunction, thyroid dysfunction, chronic inflammatory diseases, inborn errors of homocysteine, cobalamin or folate metabolism, or any other condition known to interfere with homocysteine metabolism will be excluded
- Patients who are already involved in any other trial.
- Patients not willing to fill consent/ assent form are also excluded from study.
Sites / Locations
- Smt. Kashibai Navale Medical College and General Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Control group
Test group
Arm Description
Will receive Oral saccharine tablet daily for 1month along with their existing antiepileptic therapy
Will receive Oral Folic acid 1mg tablet daily for 1month along with their existing antiepileptic therapy
Outcomes
Primary Outcome Measures
Decrease in serum homocysteine levels by 2 µmol/l
Secondary Outcome Measures
Change in baseline serum lipids
Change in baseline serum lipids following Anti-epileptic therapy will be compared between placebo and test group.
Change in baseline systolic blood pressure
Change in baseline systolic blood pressure will be compared between placebo and test group.
Full Information
NCT ID
NCT02318446
First Posted
December 10, 2014
Last Updated
December 16, 2014
Sponsor
Maharashtra University of Health Sciences
1. Study Identification
Unique Protocol Identification Number
NCT02318446
Brief Title
Efficacy Study of Folic Acid Supplementation in Adolescent Epileptics
Official Title
Efficacy Study of Folic Acid Supplementation on Homocysteine Levels in Adolescent Epileptics Taking Antiepileptic Drugs: A Single Blind Randomized Controlled Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
December 2014
Overall Recruitment Status
Unknown status
Study Start Date
March 2015 (undefined)
Primary Completion Date
April 2016 (Anticipated)
Study Completion Date
May 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Maharashtra University of Health Sciences
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The present study is planned to study effect of folic acid supplementation on homocysteine levels and CV risk factors such as BP and lipids in adolescent epileptics taking anti-epileptic drugs (AEDs).
Detailed Description
Scientific background, significance and impact value of the project:
Homocysteine is a thiol-containing amino acid formed as an intermediate product during the methionine metabolism. Re-methylation pathway recycles Homocysteine back to methionine and requires vitamin B12 and folic acid as cofactors. [1] The concentration of circulating total homocysteine is a sensitive marker of inadequate folate and vitamin B12 status. Elevated homocysteine concentrations are associated with an increased risk for cardiovascular (CV) disease. [2] The total homocysteine level is the lowest in children and an increase with age is higher in male sex. [2] The cutoffs for homocysteine level in adolescent range from 4.3 to 9.9 µmol/l, and hyperhomocysteinemia is defined as homocysteine >10.9 µmol/l. [3] Lower folate and higher homocysteine concentrations may put adolescent on AEDs at special risk for atherosclerosis in their adulthood. [4] This demands early intervention as Asian Indian adolescents are genetically more exposed to cadiovascular disease(CVD) risks, AED therapy is an additional risk for developing future CVDs. Adolescent epileptics on AED have to take it for long time, and homocysteine elevation itself has got epileptogenic potential and can cause the risk developing refractory epilepsy. [5] Literature search reveals several studies depicting role of vitamin B12 in regulation of blood homocysteine levels. [6, 7] However, the studies confirming role of folic acid supplementation in hyperhomocysteinemia and related CV diseases are fewer and scarce in AEDs induced hyperhomocysteinemia. Few studies have reported negative correlation between hyperhomocysteinemia and low folic acid levels in patients on AEDs. [8] At the same time few studies have reported effectiveness of folic acid supplementation to normalize the homocysteine levels. [9] Considering the results of various studies many doctors are now prescribing folic acid along with AEDs, although there is a scarcity of data from India. In this context, the present study is planned to study effect of folic acid supplementation on homocysteine levels and CV risk factors such as BP and lipids in adolescent epileptics taking AEDs.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epilepsy
Keywords
Anti-epileptic drugs, Folic acid, Homocysteine
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
36 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
Will receive Oral saccharine tablet daily for 1month along with their existing antiepileptic therapy
Arm Title
Test group
Arm Type
Experimental
Arm Description
Will receive Oral Folic acid 1mg tablet daily for 1month along with their existing antiepileptic therapy
Intervention Type
Drug
Intervention Name(s)
Folic Acid
Other Intervention Name(s)
Folvite
Intervention Description
Test group(n= 24) Existing Anti-epileptic Drugs + Oral Folic acid 1mg tablet daily for 1month
Intervention Type
Drug
Intervention Name(s)
Saccharine
Other Intervention Name(s)
Sugar free
Intervention Description
Placebo group(n=12) Existing Anti-epileptic Drugs + Oral saccharine 10 mg tablet daily for 1month
Primary Outcome Measure Information:
Title
Decrease in serum homocysteine levels by 2 µmol/l
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Change in baseline serum lipids
Description
Change in baseline serum lipids following Anti-epileptic therapy will be compared between placebo and test group.
Time Frame
1 month
Title
Change in baseline systolic blood pressure
Description
Change in baseline systolic blood pressure will be compared between placebo and test group.
Time Frame
1 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed epileptic patients of either sex with age between 10-19 yrs (<19yrs), coming to the medicine Out Patient /In Patient Departments and undergoing AED therapy for more than 6 months.
Epileptics with high homocysteine levels i.e. > 10.9 µmol/L (Normal homocysteine levels are 4.3-9.9 µmol/L for male and 3.3-7.2 µmol/L for female adolescent and a high homocysteine concentration is deaned as at least 11.4 µmol/L for male and at least 10.4 µmol/L for female. Gender mean of high homocysteine concentration is 10.9 µmol/L) [5]
Exclusion Criteria:
Pregnancy and lactation
Patients with diabetes, Ischemic heart disease (IHD), stroke, malignancy and psychiatric diseases are excluded from study.
The patients receiving vitamin supplements or who had clinical evidence for an acute illness, renal dysfunction, thyroid dysfunction, chronic inflammatory diseases, inborn errors of homocysteine, cobalamin or folate metabolism, or any other condition known to interfere with homocysteine metabolism will be excluded
Patients who are already involved in any other trial.
Patients not willing to fill consent/ assent form are also excluded from study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
UMA A. BHOSALE, MD
Phone
02024106
Ext
148
Email
umabhosale2000@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
UMA A. BHOSALE, MD
Organizational Affiliation
Smt. Kashibai Navale Medical College and General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Smt. Kashibai Navale Medical College and General Hospital
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411041
Country
India
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Uma A. Bhosale, MD
Phone
02024106
Ext
148
Email
umabhosale2000@gmail.com
12. IPD Sharing Statement
Citations:
PubMed Identifier
15536605
Citation
Hoffer LJ. Homocysteine remethylation and trans-sulfuration. Metabolism. 2004 Nov;53(11):1480-3. doi: 10.1016/j.metabol.2004.06.003.
Results Reference
background
PubMed Identifier
1728812
Citation
Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr. 1992 Jan;55(1):131-8. doi: 10.1093/ajcn/55.1.131.
Results Reference
background
PubMed Identifier
10475885
Citation
Selhub J, Jacques PF, Rosenberg IH, Rogers G, Bowman BA, Gunter EW, Wright JD, Johnson CL. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med. 1999 Sep 7;131(5):331-9. doi: 10.7326/0003-4819-131-5-199909070-00003.
Results Reference
background
PubMed Identifier
10199428
Citation
Osganian SK, Stampfer MJ, Spiegelman D, Rimm E, Cutler JA, Feldman HA, Montgomery DH, Webber LS, Lytle LA, Bausserman L, Nader PR. Distribution of and factors associated with serum homocysteine levels in children: Child and Adolescent Trial for Cardiovascular Health. JAMA. 1999 Apr 7;281(13):1189-96. doi: 10.1001/jama.281.13.1189.
Results Reference
background
PubMed Identifier
20051609
Citation
Cheng LS, Prasad AN, Rieder MJ. Relationship between antiepileptic drugs and biological markers affecting long-term cardiovascular function in children and adolescents. Can J Clin Pharmacol. 2010 Winter;17(1):e5-46. Epub 2010 Jan 4.
Results Reference
background
PubMed Identifier
24018893
Citation
Sato Y, Ouchi K, Funase Y, Yamauchi K, Aizawa T. Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes. Endocr J. 2013;60(12):1275-80. doi: 10.1507/endocrj.ej13-0332. Epub 2013 Sep 8.
Results Reference
background
PubMed Identifier
22069468
Citation
Satyanarayana A, Balakrishna N, Pitla S, Reddy PY, Mudili S, Lopamudra P, Suryanarayana P, Viswanath K, Ayyagari R, Reddy GB. Status of B-vitamins and homocysteine in diabetic retinopathy: association with vitamin-B12 deficiency and hyperhomocysteinemia. PLoS One. 2011;6(11):e26747. doi: 10.1371/journal.pone.0026747. Epub 2011 Nov 1.
Results Reference
background
PubMed Identifier
22425007
Citation
Coppola G, Ingrosso D, Operto FF, Signoriello G, Lattanzio F, Barone E, Matera S, Verrotti A. Role of folic acid depletion on homocysteine serum level in children and adolescents with epilepsy and different MTHFR C677T genotypes. Seizure. 2012 Jun;21(5):340-3. doi: 10.1016/j.seizure.2012.02.011. Epub 2012 Mar 16.
Results Reference
background
PubMed Identifier
21246600
Citation
Linnebank M, Moskau S, Semmler A, Widman G, Stoffel-Wagner B, Weller M, Elger CE. Antiepileptic drugs interact with folate and vitamin B12 serum levels. Ann Neurol. 2011 Feb;69(2):352-9. doi: 10.1002/ana.22229. Epub 2011 Jan 19.
Results Reference
background
PubMed Identifier
12884032
Citation
De Lourdes Levy M, Larcher V, Kurz R; Ethics Working Group of the Confederation of European Specialists in Paediatrics (CESP). Informed consent/assent in children. Statement of the Ethics Working Group of the Confederation of European Specialists in Paediatrics (CESP). Eur J Pediatr. 2003 Sep;162(9):629-33. doi: 10.1007/s00431-003-1193-z. Epub 2003 Jul 19.
Results Reference
background
PubMed Identifier
20019831
Citation
Age limits and adolescents. Paediatr Child Health. 2003 Nov;8(9):577-8. doi: 10.1093/pch/8.9.577. No abstract available.
Results Reference
background
Links:
URL
http://www.who.int/topics/adolescent_health/en/
Description
World Health Organization. [Accessed May 15, 2014]; Health topics. Adolescent health. 2011
Learn more about this trial
Efficacy Study of Folic Acid Supplementation in Adolescent Epileptics
We'll reach out to this number within 24 hrs